Emir Sokolović, Medical Oncology Resident at Clinical Center University of Sarajevo, shared a post on LinkedIn about a paper he co-authored with colleagues published in Biomolecules and Biomedicine:

“Thyroid dysfunction is a common immune-related adverse event in patients with metastatic NSCLC receiving ICIs – particularly atezolizumab – and may correlate with improved PFS.

These observations highlight the importance of systematic thyroid monitoring in this population and raise the possibility that thyroid dysfunction could serve as a surrogate marker of enhanced immunotherapy efficacy.

Further prospective research is needed to clarify the underlying mechanisms and confirm the potential prognostic value of this endocrine irAE.”

“Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study”

Authors: Šejla Cerić, Timur Cerić, Emir Sokolović, Jasmina Dalač, Dragana Miletić, Inga Marijanović, Layan Mattar, Amina Aljić, Selma Agić-Bilalagić, Amera Šadija, Miran Hadžiahmetović, Semir Bešlija.

Emir Sokolović: The need for systematic thyroid monitoring in mNSCLC patients on ICIs

More posts featuring Emir Sokolović.